Eli Lilly and Company to Freeze Base Pay, Reduce Bonuses

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

U.S. drugmaker Eli Lilly & Co (LLY.N), which expects to lose about 20 percent of its global revenue next year due to the expiration of key drug patents, is suspending base pay increases for most employees in 2014 to cut costs. At the end of this year Lilly's current biggest product, the antidepressant Cymbalta, will lose patent protection while copycat forms of its $1 billion-a-year Evista osteoporosis drug are due to arrive in early 2014. The company has also decided to reduce employee bonuses paid out in 2015 for their performance in 2014. The news came just months after the drugmaker decided to layoff about 1,000 domestic sales representatives to cut costs.

Help employers find you! Check out all the jobs and post your resume.

Back to news